These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21241212)

  • 1. Novel small molecules for the treatment of infections caused by Candida albicans: a patent review (2002-2010).
    Calugi C; Trabocchi A; Guarna A
    Expert Opin Ther Pat; 2011 Mar; 21(3):381-97. PubMed ID: 21241212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis.
    Goldman RC; Frost DJ; Capobianco JO; Kadam S; Rasmussen RR; Abad-Zapatero C
    Infect Agents Dis; 1995 Dec; 4(4):228-47. PubMed ID: 8665087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel antifungal agents: a patent review (2011 - present).
    Castelli MV; Butassi E; Monteiro MC; Svetaz LA; Vicente F; Zacchino SA
    Expert Opin Ther Pat; 2014 Mar; 24(3):323-38. PubMed ID: 24392809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.
    Trabocchi A; Mannino C; Machetti F; De Bernardis F; Arancia S; Cauda R; Cassone A; Guarna A
    J Med Chem; 2010 Mar; 53(6):2502-9. PubMed ID: 20184325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungals to treat Candida albicans.
    Moudgal V; Sobel J
    Expert Opin Pharmacother; 2010 Aug; 11(12):2037-48. PubMed ID: 20536294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.
    Beyda ND; Lewis RE; Garey KW
    Ann Pharmacother; 2012; 46(7-8):1086-96. PubMed ID: 22811350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspartic protease inhibitors: effective drugs against the human fungal pathogen Candida albicans.
    Santos AL; Braga-Silva LA
    Mini Rev Med Chem; 2013 Jan; 13(1):155-62. PubMed ID: 23256485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Candida albicans extracellular enzyme activity by selected natural substances and their application in Candida infection.
    Yordanov M; Dimitrova P; Patkar S; Saso L; Ivanovska N
    Can J Microbiol; 2008 Jun; 54(6):435-40. PubMed ID: 18535628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.
    Gruber A; Berlit J; Speth C; Lass-Flörl C; Kofler G; Nagl M; Borg-von Zepelin M; Dierich MP; Würzner R
    Immunobiology; 1999 Sep; 201(1):133-44. PubMed ID: 10532286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, inhibition studies, and molecular modeling of pepstatin analogues addressing different secreted aspartic proteinases of Candida albicans.
    Cadicamo CD; Mortier J; Wolber G; Hell M; Heinrich IE; Michel D; Semlin L; Berger U; Korting HC; Höltje HD; Koksch B; Borelli C
    Biochem Pharmacol; 2013 Apr; 85(7):881-7. PubMed ID: 23262278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.
    Rex JH; Walsh TJ; Sobel JD; Filler SG; Pappas PG; Dismukes WE; Edwards JE
    Clin Infect Dis; 2000 Apr; 30(4):662-78. PubMed ID: 10770728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current state of three-dimensional characterisation of antifungal targets and its use for molecular modelling in drug design.
    Ruge E; Korting HC; Borelli C
    Int J Antimicrob Agents; 2005 Dec; 26(6):427-41. PubMed ID: 16289513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel non-peptidic small molecule inhibitors of secreted aspartic protease 2 (SAP2) for the treatment of resistant fungal infections.
    Dong G; Liu Y; Wu Y; Tu J; Chen S; Liu N; Sheng C
    Chem Commun (Camb); 2018 Dec; 54(96):13535-13538. PubMed ID: 30431632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors.
    Migliorati CA; Birman EG; Cury AE
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Sep; 98(3):301-10. PubMed ID: 15356467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human fungal pathogen Candida albicans in the postgenomic era: an overview.
    Kabir MA; Hussain MA
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):121-34. PubMed ID: 19622061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors.
    Cassone A; De Bernardis F; Torosantucci A; Tacconelli E; Tumbarello M; Cauda R
    J Infect Dis; 1999 Aug; 180(2):448-53. PubMed ID: 10395861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candida biofilms: antifungal resistance and emerging therapeutic options.
    Kuhn DM; Ghannoum MA
    Curr Opin Investig Drugs; 2004 Feb; 5(2):186-97. PubMed ID: 15043393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candida proteases and their inhibition: prospects for antifungal therapy.
    Stewart K; Abad-Zapatero C
    Curr Med Chem; 2001 Jul; 8(8):941-8. PubMed ID: 11375761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009).
    Espinel-Ingroff A
    Rev Iberoam Micol; 2009 Mar; 26(1):15-22. PubMed ID: 19463273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Azole resistance in Candida albicans].
    Perea S
    Rev Esp Quimioter; 2000 Sep; 13(3):314-7. PubMed ID: 11086283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.